DEVELOPMENT OF ORODISPERSIBLE TABLETS OF LORATADINE CONTAINING AN AMORPHOUS SOLID DISPERSION OF THE DRUG IN SOLUPLUS® USING DESIGN OF EXPERIMENTS

HEMA A. NAIR; GAAYATHRI GADHIRAJU; GUNDETI SUNNY

doi:10.22159/ijpps.2023v15i8.47750

Authors

HEMA A. NAIR Sri Venkateshwara College of Pharmacy, Madhapur, Hyderabad-500081, Telangana, India https://orcid.org/0009-0002-2451-7074
GAAYATHRI GADHIRAJU Sri Venkateshwara College of Pharmacy, Madhapur, Hyderabad-500081, Telangana, India https://orcid.org/0009-0009-6665-8001
GUNDETI SUNNY Sri Venkateshwara College of Pharmacy, Madhapur, Hyderabad-500081, Telangana, India https://orcid.org/0009-0006-6251-5810

DOI:

https://doi.org/10.22159/ijpps.2023v15i8.47750

Keywords:

Loratadine, Soluplus®, Amorphous solid dispersions, DOE, Orodispersible tablets

Abstract

Objective: The objective of the present work was to develop an orodispersible tablet of loratadine, an orally active, non-sedating anti-histaminic, belonging to BCS Class II. The drug was prepared as a solid dispersion using Soluplus® as carrier and formulated into an optimal tablet using Design of Experiments.

Methods: Solid dispersions of loratadine with varying ratios of Soluplus® were prepared by solvent evaporation and subjected to solubility study in simulated salivary fluid. Selected composition was characterized by differential scanning calorimetry and X-ray diffraction and formulated into an orodispersible tablet by direct compression after addition of suitable excipients. DOE based on a full factorial design was used to optimize the product using a trial version of JMP software, so as to obtain a tablet with low friability, rapid disintegration and maximal drug dissolution within 5 min. The optimized tablet was prepared and evaluated for several attributes, including in vivo disintegration and palatability.

Results: A solid dispersion prepared with a 1: 4 ratio of loratadine: Soluplus® was found to show a 130-fold increase in drug solubility in the simulated salivary fluid. X-ray diffraction revealed loratadine in amorphous form. The exercise using DOE for optimization of the orodispersible tablet formula served to balance the proportion of crospovidone as super disintegrant and PVP as dry binder and yielded a formulation with good mechanical strength, rapid in vitro disintegration (39 sec) and dissolution of 93.78% of the drug within 5 min. When evaluated in vivo, the tablets were found to disintegrate in about 60 secs and were reported to be palatable.

Conclusion: A patient-friendly dosage form containing a highly soluble form of loratadine was prepared and could be of potential benefit in offering quick relief from allergic conditions.

Downloads

Download data is not yet available.

References

Ghourichay MP, Kiaie SH, Nokhodchi A, Javadzadeh Y. Formulation and quality control of orally disintegrating tablets (ODTS): recent advances and perspectives. BioMed Res Int. 2021 Dec 24:6618934. doi: 10.1155/2021/6618934, PMID 34977245.

FDA. Guidance for Industry: orally disintegrating tablets. Silver Spring, MD: Food and drug administration center for drug evaluation and research; 2008.

Orally disintegrating tablet market: global Industry Trend Analysis Forecast 2019 to 2029. Persistence market research. Available from: https://www.persistencemarketresearch.com/market-research/orally-disintegrating-tablet-market.asp. [Last accessed on 27 Feb 2023].

Stark JG, Engelking D, McMahen R, Sikes CR. Pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27(3):216-22. doi: 10.1089/cap.2016.0119, PMID 27936898.

Sidhu G, Akhondi H. Loratadine. StatPearls;2022.

Uddin MZ, Chowdhury JA, Hasan I, Reza MS. Enhancement of dissolution profile of poorly water-soluble loratadine by solid dispersion technique. Dhaka Univ J Pharm Sci. 2017;15(2):195-201. doi: 10.3329/dujps.v15i2.30937.

Nair AR, Lakshman YD, Anand VSK, Sree KSN, Bhat K, Dengale SJ. Overview of extensively employed polymeric carriers in solid dispersion technology. AAPS PharmSciTech. 2020;21(8):309. doi: 10.1208/s12249-020-01849-z, PMID 33161493.

Fule RA, Meer TS, Sav AR, Amin PD. Artemether Soluplus hot-melt extrudate solid dispersion systems for solubility and dissolution rate enhancement with amorphous state characteristics. J Pharm (Cairo). 2013;2013:151432. doi: 10.1155/2013/151432, PMID 26555968.

Pignatello R, Corsaro R, Bonaccorso A, Zingale E, Carbone C, Musumeci T. Soluplus® polymeric nanomicelles improve solubility of BCS-class II drugs. Drug Deliv Transl Res. 2022;12(8):1991-2006. doi: 10.1007/s13346-022-01182-x, PMID 35604634.

Peh KK, Wong CF. Polymeric films as vehicle for buccal delivery: swelling, mechanical, and bioadhesive properties. J Pharm Pharm Sci. 1999;2(2):53-61. PMID 10952770.

Abdullah Ali H, Kamal Omer H. Solubility enhancement of a poorly water-soluble drug using hydrotropy and mixed hydrotropic-based solid dispersion techniques. Adv Pharmacol Pharm Sci. 2022;2022:7161660. doi: 10.1155/2022/7161660, PMID 36479276.

Piccinni P, Tian Y, McNaughton A, Fraser J, Brown S, Jones DS. Solubility parameter-based screening methods for early-stage formulation development of itraconazole amorphous solid dispersions. J Pharm Pharmacol. 2016 May;68(5):705-20. doi: 10.1111/jphp.12491, PMID 26864155.

Borde S, Shahi SR, Kale KV, Jadhav AC, Parakh DR. Formulation and evaluation of paliperidone HCl mouth dissolving tablet by QbD approach. Pharm Biol Eval. 2016;3:528-40.

Indian pharmacopoeia, Government of India, Ministry of Health and Family Welfare, controller of publications. New Delhi; 2022.

Gupta MM, Gupta N, Chauhan BS, Pandey S. Fast disintegrating combination tablet of taste masked levocetrizine dihydrochloride and montelukast sodium: formulation design, development, and characterization. J Pharm (Cairo). 2014;2014:568320. doi: 10.1155/2014/568320, PMID 26556198.

Nair HA, Pyla D. Formulation of glimepiride oral films and development of a novel disintegration time testing method for its evaluation. J Pharm Sci Res. 2022;14(9):894-900.

Wu G, Baraldo M, Furlanut M. Calculating percentage prediction error: a user’s note. Pharmacol Res. 1995;32(4):241-8. doi: 10.1016/s1043-6618(05)80029-5, PMID 8866841.

Choudhury P, Deb P, Dash S. Formulation and statistical optimization of bilayer sublingual tablets of levocetirizine hydrochloride and ambroxol hydrochloride. Asian J Pharm Clin Res. 2016;9(5):228-34. doi: 10.22159/ajpcr.2016.v9i5.13343.

Parikh T, Gupta SS, Meena AK, Vitez I, Mahajan N, Serajuddin ATM. Application of the film-casting technique to investigate drug–polymer miscibility in solid dispersion and hot-melt extrudate. J Pharm Sci. 2015;104(7):2142-52. doi: 10.1002/jps.24446, PMID 25917333.

Khan MZ, Rausl D, Zanoski R, Zidar S, Mikulcic JH, Krizmanic L. Classification of loratadine based on the biopharmaceutics drug classification concept and possible in vitro-in vivo correlation. Biol Pharm Bull. 2004;27(10):1630-5. doi: 10.1248/bpb.27.1630, PMID 15467209.

Sofroniou C, Baglioni M, Mamusa M, Resta C, Doutch J, Smets J. Self-assembly of soluplus in aqueous solutions: characterization and prospectives on perfume encapsulation. ACS Appl Mater Interfaces. 2022;14(12):14791-804. doi: 10.1021/acsami.2c01087, PMID 35312278.

Zhong Y, Jing G, Tian B, Huang H, Zhang Y, Gou J. Supersaturation induced by itraconazole/soluplus® micelles provided high GI absorption in vivo. Asian J Pharm Sci. 2016;11(2):255-64. doi: 10.1016/j.ajps.2015.07.001.

Scheubel E, Lindenberg M, Beyssac E, Cardot JM. Small-volume dissolution testing as a powerful method during pharmaceutical development. Pharmaceutics. 2010;2(4):351-63. doi: 10.3390/pharmaceutics2040351, PMID 27721362.